Nykode Therapeutics to Present a Poster on Interim Results from the Pre-planned Interim Analysis from the C-02 trial with VB10.16 in advanced cervical patients at the European Society of Gynaecological Oncology’s 23rd Annual Meeting (ESGO 2022)

On October 28, 2022 Nykode Therapeutics ASA (OSE: NYKD), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, reported the presentation of a poster at the European Society of Gynaecological Oncology’s 23rd Annual Meeting, being held in Berlin, October 27-30 (Press release, Nykode Therapeutics, OCT 28, 2022, View Source [SID1234622555]). The presentations will include results from a pre-planned interim analysis of the VB C-02 trial with VB10.16, Nykode’s wholly owned therapeutic DNA vaccine specifically targeting antigen presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new data further supports the use of specific blood based biomarkers as prognostic and predictive factors of treatment outcome.

Michael Engsig, Nykode’s Chief Executive Officer, stated: "It is a great opportunity to present the VB C-02 interim data, including data that have not been released before, to the scientific community at ESGO. We look forward to continue updating the scientific community as we dive deeper into the interim data of VB C-02 to further our understanding of how VB10.16 works to the benefit of patients and how biomarkers can be used to predict clinical outcome."

Poster accepted for presentation at ESGO 2022 Abstract ID 447; PA-004:

• Efficacy and safety of VB10.16, therapeutic DNA vaccine specifically targeting antigen presenting cells, in combination with atezolizumab in patients with advanced HPV16-positive cervical cancer: results from a pre-planned interim analysis

The poster will be made available in the Scientific Papers and Presentations section of the Company’s website at View Source